Director — Tim Ruan: A director resigned immediately without any stated disagreement, representing a standard board departure rather than a senior executive loss or conflict.

Entry into a Material Definitive Agreement. On August 28, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into an Amended and Restated At the Market Offering Agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (“ Wainwright ”), which amends and restates in its entirety, and supersedes and replaces, the At The Market Offering Agreement, dated June 1, 2022, between the Company and Wainwright (the “ Original Agreement ”). The Sales Agreement provides for the sale and…

Results of Operations and Financial Condition. On August 13, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) issued a press release (the “ Press Release ”) announcing its financial results for the quarter ended June 30, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Press Release contains certain business updates and forward-looking statements regarding the Company’s expectations, plans and prospects. The information in this Current…

Entry into a Material Definitive Agreement. On June 17, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with certain non-U.S. accredited investors named therein (collectively, the “ Purchasers ”), pursuant to which the Company agreed to issue and sell an aggregate of 20,000,000 shares of its common stock, par value $0.01 per share (the “ Common Stock ”), at a purchase price of $0.60 per share (the “ Private Placement ”).…

Unregistered Sales of Equity Securities. The information set forth in

Director, Chief Operating Officer — Mr. David E. Lazar, Mr. Avraham Ben-Tzvi, Mr. Walt A. Linscott, Esq.: Multiple senior executives and directors resigned from their positions.

Results of Operations and Financial Condition. On May 15, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) issued a press release (the “ Press Release ”) announcing its financial results for the quarter ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Press Release contains certain business updates and forward-looking statements regarding the Company’s expectations, plans and prospects. The information in this Current Re…

Director — Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith: The company appointed two new independent directors to the Board.

Director — Mr. Tim Ruan and Dr. Yi Zhang: The company appointed two new independent directors to the Board.

Chief Financial Officer — Nir Sassi: Nir Sassi resigned as Chief Financial Officer without a stated disagreement.

co-Chief Executive Officer, Director — Jeffrey A. Meckler, David Lazar: Multiple directors and officers resigned without a named successor.

of the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “Company”) on December 23, 2025, on December 22, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he purchased from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series AAA Convertible Preferred Stock (the “Series AAA Preferred Stock” and, together with the Serie…

Changes in Control of Registrant. As described in

Material Modification to Rights of Security Holders. As described below under

Changes in Control of Registrant As described below under

Unregistered Sales of Equity Securities. The information under

Entry into a Material Definitive Agreement. On February 11, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into warrant repricing agreements (the “Repricing Agreements”) with certain holders (the “Executing Holders”) of warrants to purchase an aggregate of 913,638 shares of common stock of the Company that were originally issued in financing rounds during 2024 and 2025 at exercise prices ranging from $8.30 to $47.60 (the “Executing Warrants”). Pursuant to the Repricing Agreements,…

The salaries of the Executive Officers were adjusted to $60,000 per annum.

Director — Michael Newman, Mark Gilbert, and Anthony Maddaluna: Three directors resigned from the Board of Directors.

Director — Robert E. Martell and Hila Karah: The resignation of the directors is not based on any disagreement with the Company, but it still represents a significant change in the board composition.

Unregistered Sales of Equity Securities. The disclosure required by this Item and included in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 22, 2025, Indaptus, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he agreed to purchase from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series AAA Convertible Preferred Stock (the “Series AAA Preferred Stock” and, together with the Series AA Pr…

Material Modifications to Rights of Security Holders. The disclosure required by this Item and included in

Results of Operations and Financial Condition. On November 12, 2025, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securiti…

Results of Operations and Financial Condition. On August 13, 2025, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exch…